Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
lung cancer
Advertisement
Bayer’s Asundexian Wins FDA Priority Review
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
MEKanistic Clears FDA IND for MTX-531 Cancer Trial
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Advertisements
Genentech Highlights Giredestrant Data at ASCO 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
Nuvation Bio Expands IBTROZI FDA Lung Cancer Filing
NEW YORK, May 6, 2026 Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food...
Nuvalent ALKOVE-1 Data Boosts NSCLC Targeted Therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
Advertisement
